Logo image of CABA

CABALETTA BIO INC (CABA) Stock Fundamental Analysis

NASDAQ:CABA - Nasdaq - US12674W1099 - Common Stock - Currency: USD

1.99  +0.03 (+1.53%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CABA. CABA was compared to 571 industry peers in the Biotechnology industry. While CABA has a great health rating, there are worries on its profitability. CABA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CABA has reported negative net income.
In the past year CABA has reported a negative cash flow from operations.
In the past 5 years CABA always reported negative net income.
In the past 5 years CABA always reported negative operating cash flow.
CABA Yearly Net Income VS EBIT VS OCF VS FCFCABA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -50.96%, CABA perfoms like the industry average, outperforming 47.06% of the companies in the same industry.
The Return On Equity of CABA (-59.78%) is better than 60.43% of its industry peers.
Industry RankSector Rank
ROA -50.96%
ROE -59.78%
ROIC N/A
ROA(3y)-36.2%
ROA(5y)-30.68%
ROE(3y)-39.53%
ROE(5y)-33.03%
ROIC(3y)N/A
ROIC(5y)N/A
CABA Yearly ROA, ROE, ROICCABA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 50 -50 100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CABA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CABA Yearly Profit, Operating, Gross MarginsCABA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, CABA has more shares outstanding
Compared to 5 years ago, CABA has more shares outstanding
CABA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CABA Yearly Shares OutstandingCABA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
CABA Yearly Total Debt VS Total AssetsCABA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -1.16, we must say that CABA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CABA (-1.16) is comparable to the rest of the industry.
CABA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.16
ROIC/WACCN/A
WACCN/A
CABA Yearly LT Debt VS Equity VS FCFCABA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

2.3 Liquidity

CABA has a Current Ratio of 8.11. This indicates that CABA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.11, CABA is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
A Quick Ratio of 8.11 indicates that CABA has no problem at all paying its short term obligations.
The Quick ratio of CABA (8.11) is better than 72.91% of its industry peers.
Industry RankSector Rank
Current Ratio 8.11
Quick Ratio 8.11
CABA Yearly Current Assets VS Current LiabilitesCABA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CABA have decreased strongly by -25.73% in the last year.
EPS 1Y (TTM)-25.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CABA will show a small growth in Earnings Per Share. The EPS will grow by 0.82% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-44.58%
EPS Next 2Y-25.32%
EPS Next 3Y-17.9%
EPS Next 5Y0.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CABA Yearly Revenue VS EstimatesCABA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CABA Yearly EPS VS EstimatesCABA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CABA. In the last year negative earnings were reported.
Also next year CABA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CABA Price Earnings VS Forward Price EarningsCABA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CABA Per share dataCABA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as CABA's earnings are expected to decrease with -17.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.32%
EPS Next 3Y-17.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CABA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CABALETTA BIO INC

NASDAQ:CABA (2/25/2025, 10:17:31 AM)

1.99

+0.03 (+1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners79.53%
Inst Owner Change-98.18%
Ins Owners3.09%
Ins Owner Change0%
Market Cap97.27M
Analysts84.44
Price Target21.01 (955.78%)
Short Float %13.2%
Short Ratio3.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.09%
Min EPS beat(2)-1.96%
Max EPS beat(2)-0.22%
EPS beat(4)0
Avg EPS beat(4)-5.56%
Min EPS beat(4)-14.93%
Max EPS beat(4)-0.22%
EPS beat(8)3
Avg EPS beat(8)0.15%
EPS beat(12)7
Avg EPS beat(12)6.75%
EPS beat(16)10
Avg EPS beat(16)6.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.19%
PT rev (3m)-6.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.04%
EPS NY rev (1m)-1.12%
EPS NY rev (3m)-4.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-2.59
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.67
OCFYN/A
SpS0
BVpS3.56
TBVpS3.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.96%
ROE -59.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.2%
ROA(5y)-30.68%
ROE(3y)-39.53%
ROE(5y)-33.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 128.06%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.11
Quick Ratio 8.11
Altman-Z -1.16
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)138.69%
Cap/Depr(5y)257.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.57%
EPS Next Y-44.58%
EPS Next 2Y-25.32%
EPS Next 3Y-17.9%
EPS Next 5Y0.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-68.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-77.99%
EBIT Next 3Y-38.01%
EBIT Next 5YN/A
FCF growth 1Y-77.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-82.15%
OCF growth 3YN/A
OCF growth 5YN/A